Novartis Achieves Multiple Sclerosis Win with BTK Inhibitor
Source Summary
Novartis has achieved a positive outcome with a BTK inhibitor for multiple sclerosis treatment. The announcement is part of broader biotech developments including additional Trump administration drug pricing agreements and GSK's accelerated mRNA flu vaccine development.
Why it matters
BTK inhibitor approval for multiple sclerosis expands Novartis's treatment portfolio for a serious neurological condition affecting millions of patients.
